Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Intestinal transit-amplifying cells require METTL3 for growth factor signaling and cell survival
Charles H. Danan, Kaitlyn E. Naughton, Katharina E. Hayer, Sangeevan Vellappan, Emily A. McMillan, Yusen Zhou, Rina Matsuda, Shaneice K. Nettleford, Kay Katada, Louis R. Parham, Xianghui Ma, Afrah Chowdhury, Benjamin J. Wilkins, Premal Shah, Matthew D. Weitzman, Kathryn E. Hamilton
Charles H. Danan, Kaitlyn E. Naughton, Katharina E. Hayer, Sangeevan Vellappan, Emily A. McMillan, Yusen Zhou, Rina Matsuda, Shaneice K. Nettleford, Kay Katada, Louis R. Parham, Xianghui Ma, Afrah Chowdhury, Benjamin J. Wilkins, Premal Shah, Matthew D. Weitzman, Kathryn E. Hamilton
View: Text | PDF
Research Article Gastroenterology

Intestinal transit-amplifying cells require METTL3 for growth factor signaling and cell survival

  • Text
  • PDF
Abstract

Intestinal epithelial transit-amplifying cells are essential stem progenitors required for intestinal homeostasis, but their rapid proliferation renders them vulnerable to DNA damage from radiation and chemotherapy. Despite these cells’ critical roles in intestinal homeostasis and disease, few studies have described genes that are essential to transit-amplifying cell function. We report that RNA methyltransferase-like 3 (METTL3) is required for survival of transit-amplifying cells in the murine small intestine. Transit-amplifying cell death after METTL3 deletion was associated with crypt and villus atrophy, loss of absorptive enterocytes, and uniform wasting and death in METTL3-depleted mice. Sequencing of polysome-bound and methylated RNAs in enteroids and in vivo demonstrated decreased translation of hundreds of methylated transcripts after METTL3 deletion, particularly transcripts involved in growth factor signal transduction such as Kras. Further investigation verified a relationship between METTL3 and Kras methylation and protein levels in vivo. Our study identifies METTL3 as an essential factor supporting the homeostasis of small intestinal tissue via direct maintenance of transit-amplifying cell survival. We highlight the crucial role of RNA modifications in regulating growth factor signaling in the intestine with important implications for both homeostatic tissue renewal and epithelial regeneration.

Authors

Charles H. Danan, Kaitlyn E. Naughton, Katharina E. Hayer, Sangeevan Vellappan, Emily A. McMillan, Yusen Zhou, Rina Matsuda, Shaneice K. Nettleford, Kay Katada, Louis R. Parham, Xianghui Ma, Afrah Chowdhury, Benjamin J. Wilkins, Premal Shah, Matthew D. Weitzman, Kathryn E. Hamilton

×

Figure 3

Intestinal distortion and mortality after METTL3 deletion are microbiota independent.

Options: View larger image (or click on image) Download as PowerPoint
Intestinal distortion and mortality after METTL3 deletion are microbiota...
(A) Log2 fold-change in serum cytokines in mice 9 days after final tamoxifen injection; ns indicates P > 0.05 for the KO versus control comparison for each individual cytokine. Statistical outliers were removed in GraphPad Prism v9.3 using ROUT method (Q = 1%). (B) Spleen weight 9 days after final tamoxifen injection. (C and D) Small intestine and colon length 9 days after final tamoxifen injection. (E) Experimental schematic depicting timing of antibiotic (abx) treatment, tamoxifen injection, and sacrifice. (F) Log2 fold-change in 16S rRNA amplified from fecal bacterial DNA on final day of tamoxifen injection in antibiotic-treated or water vehicle mice. (G) Kaplan-Meier survival curves through 15 days after final tamoxifen injection in antibiotic-treated mice; P value corresponds to log-rank (Mantel-Cox) test. (H) Weight change after final tamoxifen injection in antibiotic-treated mice, presented as mean ± SD. P value represents unpaired parametric Student’s t test for values at 8 days after final tamoxifen injection. (I) Representative H&E images from matched sections of distal small intestine in n = 3 antibiotic-treated mice per genotype. Unless otherwise noted, each data point represents a single mouse with bar at median value, and P denotes value of unpaired parametric Student’s t test. Scale bar 100 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts